BioPharma Dive December 6, 2024
Amy Baxter

A Johns Hopkins surgeon, Marty Makary also serves as a board member or adviser to several companies, including one that offers compounded GLP-1 drugs.

Robert F. Kennedy Jr., chosen by President-elect Donald Trump to be the next health secretary, has made it his mission to dissipate what he describes as a “smothering cloud of corporate capture” within agencies like the Food and Drug Administration.

In particular, he aims to target perceived conflicts of interest among health officials, a goal seemingly shared by Trump’s choice to run the FDA, Johns Hopkins surgeon and medical researcher Marty Makary. But while Trump picked Makary to “course-correct and refocus” the agency, Makary will face scrutiny of his own background once Senate confirmation hearings get...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Congress / White House, FDA, Govt Agencies
Related Articles:
FDA approves 1st monotherapy drug for treatment-resistant depression
FDA's AI Lifecycle & Scientific Information Guidance Documents
Opinion: Three former FDA officials: Here’s what Trump and his nominees need to know
Inflammatix Scores FDA Approval for Precision Infection Test
FDA Approves Spravato as Monotherapy for Major Depressive Disorder

Share This Article